FBG, I'm not here to start a fight. I apologize for being aggressive in my last post.
It does seem to me, though, if you're going to make a point repeatedly that you owe it to the board to back up your opinion with reasonable analysis and not just "I think....". Someone else asked if there's a standard by which we can objectively determine if DOC's RSU's and options are egregious. I provided a standard. I felt with your focus on DOC's equity emoluments you would be able to easily provide the needed information. I presumed you've claimed DOC has been given too much because you know how much that is.
Your first response to my comment about a standard was to hand wave it off. So, I came back at you... and I will plead guilty to being overly aggressive and personal in my comment.
So, if we can, let's have a reset. My question remains: what % of ADXS does DOC have with his equity/ options grants? Knowing the answer will give us some sense if the charge that DOC has been greedy is warranted. Investors frequently give newly hired CEO's RSU's and/ or options as enticement to join, especially where the viability of the company is in question and a turnaround will be difficult, as was the case with ADXS. Good execs are not cheap and Dan has proven himself a good executive based on clnical progress and capital raises. As to the charge he has not created shareholder value above the value of the new equity he has raised, (1) it's too early to judge by that criteria because of the long cycle times in biotech between effective lab/ clinical work and realized market value (5+ years often), and (2) the general meltdown in biotech valuations in the last 18 months.
I understand you think DOC has been given unjustified RSU compensation. Fair question and maybe that's true. I am just asking for facts against which to test that hypothesis which I thought you would have readily available.
As for another commenter's point that I'm new to this board, that's not really true. I don't post often, but I've been here for more than a year (if memory serves). I've been invested in ADXS since early 2014 when J&E from YMB got me interested in this company. But even if I were new, I think my question, if not my tone, is reasonable.
And, FBG, I do appreciate your broad due diligence on ADXS -- I was just trying to shed more light on the DOC compensation issue that has been the subject of many posts on this board.
